NCT04515719View on ClinicalTrials.gov

Efficacy and Safety of Belimumab in SLE Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

April 10, 2022

Study Completion Date

April 10, 2022

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Belimumab

Belimumab 2mg/kg intravenously

BIOLOGICAL

Placebo

Placebo intravenously

Trial Locations (1)

Unknown

Shuang Ye, MD, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT04515719 - Efficacy and Safety of Belimumab in SLE Patients | Biotech Hunter | Biotech Hunter